KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Income (2016 - 2025)

Historic Operating Income for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $115.6 million.

  • Sarepta Therapeutics' Operating Income rose 1658744.65% to $115.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $298.8 million, marking a year-over-year increase of 68646.12%. This contributed to the annual value of $218.1 million for FY2024, which is 18142.7% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Operating Income of $115.6 million as of Q2 2025, which was up 1658744.65% from $161.7 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Operating Income registered a high of $161.7 million during Q4 2024, and its lowest value of -$211.1 million during Q2 2022.
  • Moreover, its 5-year median value for Operating Income was -$86.9 million (2022), whereas its average is -$54.7 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Operating Income plummeted by 28120.32% in 2022 and then skyrocketed by 1658744.65% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Operating Income stood at -$105.8 million in 2021, then dropped by 0.96% to -$106.8 million in 2022, then surged by 123.05% to $24.6 million in 2023, then surged by 556.57% to $161.7 million in 2024, then decreased by 28.52% to $115.6 million in 2025.
  • Its Operating Income stands at $115.6 million for Q2 2025, versus $161.7 million for Q4 2024 and $22.2 million for Q3 2024.